Dr. Clay Siegall, founder of Seattle Genetics

Dr. Clay Siegall is the CEO and founder of Seattle Genetics. Founded in 1998, Seattle Genetics is a biotech firm specializing in the developement of therapy drugs for diseases with high mortality rates that have not seen a decrease in decades. Dr. Siegall has lead his firm in the targeted threapy industry. He invented the first FDA-approved antibody drug conjugate. He has partnerships with such drug manufacturers as Bayer, Pfizer, Genentech and several more. Dr. Siegall has a B.S in zoology from the University of Maryland and a Ph.D from George Washington University in Genetics. Seattle Genetics has become a leading power player in cancer research under Dr. Siegall’s leadership.

Dr. Clay Siegall specifically became interested in alternate cancer fighting drugs when a close relative was diagnosed with cancer. It was not the cancer that nearly killed this relative, it was the chemotherapy and annemia that they developed. This is what prompted Dr. Siegall to search for another way. Combined with him being a self confessed work-aholic, he decided to leave Bristol and start up Seattle Genetics. The first ten years of Seattle Genetics was financially insecure. Operating capital was being depleted and having a drug approved by the FDA can take quite a few years. The first drug the FDA approved was conjugate and and this was the first ADC ever approved by the FDA. Seattle Genetics gains clients through a talented sales staff.

In January of 2013 Mirna Therapeutics announced the appointment of Dr. Siegall as an outside director to is board of Directors. Mirna Therapeutics is a biotechnology company focused on the developement and commercialization of microRNA therapeutics. He also serves on the board at Alder BioPharmaceuticals. Alder BioPharmaceuticals is a private biotechnology company. Dr. Siegall has secured Seattle Genetics more than $675 million through private and public financings. He has written more then seventy publications and currently has over fifteen patents

Leave a Reply

Your email address will not be published. Required fields are marked *